NO320368B1 - Anvendelse av inhibitorer av natrium-hydrogen-utvekslere for fremstilling av et medikament for behandling og profylakse av sykdommer forarsaket av protozoer - Google Patents
Anvendelse av inhibitorer av natrium-hydrogen-utvekslere for fremstilling av et medikament for behandling og profylakse av sykdommer forarsaket av protozoer Download PDFInfo
- Publication number
- NO320368B1 NO320368B1 NO19983943A NO983943A NO320368B1 NO 320368 B1 NO320368 B1 NO 320368B1 NO 19983943 A NO19983943 A NO 19983943A NO 983943 A NO983943 A NO 983943A NO 320368 B1 NO320368 B1 NO 320368B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- prophylaxis
- inhibitor
- drug
- exchanger according
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 36
- 239000003112 inhibitor Substances 0.000 title claims description 33
- 238000011321 prophylaxis Methods 0.000 title claims description 24
- 239000003814 drug Substances 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 title claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 title description 4
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 title description 4
- 201000004792 malaria Diseases 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 208000003495 Coccidiosis Diseases 0.000 claims description 4
- 206010023076 Isosporiasis Diseases 0.000 claims description 4
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 206010035501 Plasmodium malariae infection Diseases 0.000 claims description 3
- 206010035503 Plasmodium vivax infection Diseases 0.000 claims description 3
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 230000009278 visceral effect Effects 0.000 claims description 3
- CCQORBUUNVVMQX-UHFFFAOYSA-N 4-[4-(2-aminoethyl)phenoxy]-n-(diaminomethylidene)-3-methylsulfonylbenzamide Chemical compound CS(=O)(=O)C1=CC(C(=O)NC(N)=N)=CC=C1OC1=CC=C(CCN)C=C1 CCQORBUUNVVMQX-UHFFFAOYSA-N 0.000 claims description 2
- HECQGFJMONDOIM-UHFFFAOYSA-N n-(diaminomethylidene)-4-pyridin-3-yloxy-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC(C(=O)NC(=N)N)=CC=C1OC1=CC=CN=C1 HECQGFJMONDOIM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 4
- 201000008680 babesiosis Diseases 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000223836 Babesia Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000009182 Parasitemia Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 241000223929 Sarcocystidae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000223838 Babesia bovis Species 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001473628 Sarcocystis suihominis Species 0.000 description 1
- 241000223777 Theileria Species 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 208000001117 Theileriasis Diseases 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000012105 intracellular pH reduction Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19737463A DE19737463A1 (de) | 1997-08-28 | 1997-08-28 | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983943D0 NO983943D0 (no) | 1998-08-27 |
| NO983943L NO983943L (no) | 1999-03-01 |
| NO320368B1 true NO320368B1 (no) | 2005-11-28 |
Family
ID=7840411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983943A NO320368B1 (no) | 1997-08-28 | 1998-08-27 | Anvendelse av inhibitorer av natrium-hydrogen-utvekslere for fremstilling av et medikament for behandling og profylakse av sykdommer forarsaket av protozoer |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6114393A (ja) |
| EP (1) | EP0901788A3 (ja) |
| JP (1) | JPH11171792A (ja) |
| KR (1) | KR100567144B1 (ja) |
| CN (1) | CN1244322C (ja) |
| AR (1) | AR013949A1 (ja) |
| AU (1) | AU738599B2 (ja) |
| BR (1) | BR9803243A (ja) |
| CA (1) | CA2246407A1 (ja) |
| CZ (1) | CZ296815B6 (ja) |
| DE (1) | DE19737463A1 (ja) |
| HK (1) | HK1018589A1 (ja) |
| HR (1) | HRP980468A2 (ja) |
| HU (1) | HU225583B1 (ja) |
| ID (1) | ID20794A (ja) |
| IL (1) | IL125946A0 (ja) |
| MY (1) | MY137406A (ja) |
| NO (1) | NO320368B1 (ja) |
| NZ (1) | NZ331566A (ja) |
| PL (1) | PL191267B1 (ja) |
| RU (1) | RU2225726C2 (ja) |
| SG (1) | SG74074A1 (ja) |
| SK (1) | SK285457B6 (ja) |
| TR (1) | TR199801669A2 (ja) |
| TW (1) | TW592690B (ja) |
| ZA (1) | ZA987781B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
| MXPA02006328A (es) * | 1999-12-23 | 2002-12-13 | Pfizer Prod Inc | Forma de dosificacion de farmacos accionada por un hidrogel. |
| US7375138B2 (en) * | 2002-05-18 | 2008-05-20 | Sanofi-Aventis Deutschland Gmbh | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them |
| FR2840302B1 (fr) * | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| US6878748B2 (en) | 2002-06-13 | 2005-04-12 | Aventis Pharma Deutschland Gmbh | Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them |
| CA3069046A1 (en) * | 2017-07-04 | 2019-01-10 | Sanofi | Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1336871A (en) * | 1970-01-02 | 1973-11-14 | Wellcome Found | Method for preparing biologically active substituted amidines |
| US4032655A (en) * | 1974-05-15 | 1977-06-28 | Bayer Aktiengesellschaft | Phenylguanidines useful as anthelmintic agents |
| US4088780A (en) * | 1974-05-15 | 1978-05-09 | Bayer Aktiengesellschaft | Substituted phenylguanidines and processes for their preparation and use |
| US4544670A (en) * | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
| DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
| IN172842B (ja) * | 1990-05-17 | 1993-12-11 | Boots Pharmaceuticals Limited | |
| ATE158589T1 (de) * | 1991-11-22 | 1997-10-15 | Yeda Res & Dev | Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen |
| CZ284456B6 (cs) * | 1992-02-15 | 1998-12-16 | Hoechst Aktiengesellschaft | Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje |
| GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
| DE4318658A1 (de) * | 1993-06-04 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4318756A1 (de) * | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19502644A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | 4-Amino-benzoylguanidin-Derivate |
| FR2734263B1 (fr) * | 1995-05-17 | 1997-06-20 | Fournier Ind & Sante | Analogues de la 15-deoxyspergualine, leur procede de preparation et leur utilisation en therapeutique |
| ES2216049T3 (es) * | 1995-06-07 | 2004-10-16 | Genaera Corporation | Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos. |
| DE19542306A1 (de) * | 1995-11-14 | 1997-05-15 | Hoechst Ag | Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
1997
- 1997-08-28 DE DE19737463A patent/DE19737463A1/de not_active Withdrawn
-
1998
- 1998-08-24 EP EP98115902A patent/EP0901788A3/de not_active Withdrawn
- 1998-08-26 CZ CZ0272998A patent/CZ296815B6/cs not_active IP Right Cessation
- 1998-08-26 TR TR1998/01669A patent/TR199801669A2/xx unknown
- 1998-08-26 SK SK1174-98A patent/SK285457B6/sk unknown
- 1998-08-26 AR ARP980104256A patent/AR013949A1/es unknown
- 1998-08-26 CA CA002246407A patent/CA2246407A1/en not_active Abandoned
- 1998-08-26 US US09/140,544 patent/US6114393A/en not_active Expired - Fee Related
- 1998-08-26 HU HU9801925A patent/HU225583B1/hu not_active IP Right Cessation
- 1998-08-26 NZ NZ331566A patent/NZ331566A/en unknown
- 1998-08-26 IL IL12594698A patent/IL125946A0/xx not_active IP Right Cessation
- 1998-08-26 ID IDP981166A patent/ID20794A/id unknown
- 1998-08-27 CN CNB981184928A patent/CN1244322C/zh not_active Expired - Fee Related
- 1998-08-27 RU RU98116380/15A patent/RU2225726C2/ru not_active IP Right Cessation
- 1998-08-27 KR KR1019980034759A patent/KR100567144B1/ko not_active IP Right Cessation
- 1998-08-27 JP JP10241376A patent/JPH11171792A/ja not_active Abandoned
- 1998-08-27 BR BR9803243A patent/BR9803243A/pt not_active Application Discontinuation
- 1998-08-27 SG SG1998003335A patent/SG74074A1/en unknown
- 1998-08-27 HR HR19737463.8A patent/HRP980468A2/hr not_active Application Discontinuation
- 1998-08-27 AU AU81894/98A patent/AU738599B2/en not_active Ceased
- 1998-08-27 ZA ZA987781A patent/ZA987781B/xx unknown
- 1998-08-27 MY MYPI98003946A patent/MY137406A/en unknown
- 1998-08-27 NO NO19983943A patent/NO320368B1/no unknown
- 1998-08-28 PL PL328265A patent/PL191267B1/pl not_active IP Right Cessation
- 1998-09-23 TW TW087114024A patent/TW592690B/zh not_active IP Right Cessation
-
1999
- 1999-07-28 HK HK99103255A patent/HK1018589A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robert et al. | Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. | |
| Schein | Equine babesiosis | |
| Rebec et al. | Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs | |
| Chinchilla et al. | An in vivo model to study the anti-malaric capacity of plant extracts | |
| NO320368B1 (no) | Anvendelse av inhibitorer av natrium-hydrogen-utvekslere for fremstilling av et medikament for behandling og profylakse av sykdommer forarsaket av protozoer | |
| Bishop et al. | Sulphadiazine-resistance in Plasmodium gallinaceum and its relation to other antimalarial compounds | |
| Gillet et al. | Plasmodium berghei: Inhibition of the sporogonous cycle by α-difluoromethylornithine | |
| Contini et al. | Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia | |
| Zhang et al. | The state of art of extracellular traps in protozoan infections | |
| Borowy et al. | Ro 15–0216: a nitroimidazole compound active in vitro against human and animal pathogenic African trypanosomes | |
| Ramakrishnan et al. | Studies on the toxicity and action of diaminodiphenylsulfone (DDS) in avian and simian malaria | |
| Kaminsky et al. | Effect of in vitro cultivation on the stability of resistance of Trypanosoma brucei brucei to diminazene, isometamidium, quinapyramine, and Mel B | |
| Eastham et al. | The activity of pyrimethamine and sulphadoxine against Plasmodium falciparum determined by the in vitro microtechnique | |
| Okubo et al. | Calcium-ions are involved in erythrocyte invasion by equine Babesia parasites | |
| Egbe-Nwiyi et al. | The therapeutic efficacy of artesunate and diminazene in the treatment of experimental Trypanosoma brucei brucei infection in rats | |
| Haraguchi et al. | Prevalence of Anti-parasitic Drug Resistance in Various Areas of the World | |
| SCHWARTZ et al. | Current concepts of malaria: with a review of five hundred and ten admissions to a veterans hospital | |
| EP1140100A2 (en) | Use of (s)-triazines for treating apicomplexan parasitic infections | |
| Oduola et al. | Plasmodium berghei: efficacy and safety of combinations of chloroquine and promethazine in chloroquine resistant infections in gravid mice. | |
| Wells | A meander through malaria | |
| Poindexter | Human malaria. | |
| Olayemi et al. | In vivo EVALUATION OF WEAVER ANT (Oecophylla smaragdina) EXTRACTS ON HEMATOLOGICAL STATUS AND LIVER FUNCTION INDICES OF Plasmodium berghei INFECTED MICE | |
| Adeniyi et al. | In vivo Evaluation of Weaver Ant (Oecophylla smaragdina) Extracts on Haematological Status and Liver Function Indices of Plasmodium berghei infected Mice | |
| Temporini et al. | Lycopodiumclavatum and Conium Maculatum effect on Hearts of Mice Infected with Trypanosomacruzi | |
| Schulemann et al. | Retrospections and perspectives of chemotherapy of malaria |